← Johnson & Johnson

What podcasts say about Johnson & Johnson

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about Johnson & Johnson

68 statements · 63 positive · 2 negative · 1 mixed · 2 neutral

  1. Lauren MartzNeutralNov 17, 2026· BioCentury This Week

    The Allen transaction includes more than $1.1 billion in regulatory and commercial milestones.

    “There's another 1.1 or a little more. in regulatory and commercial milestones.”

    Listen at 2:18

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  2. John CerteauNeutralNov 16, 2026· Brew Markets

    Johnson & Johnson is buying All In Biosciences for over $2 billion.

    “the drugmaker is buying iDisease Biotech Company All In Biosciences for over $2 billion.”

    Listen at 17:04

    Open the episode · NVIDIA's China Loophole & The Aviation Blame Game
  3. Contessa BrewerPositiveNov 14, 2026· CNBC's "Fast Money"

    Johnson & Johnson will likely continue growth and dividend payments.

    “I think you're gonna likely continue to see some growth, continue to see that dividend.”

    Listen at 37:29

    Open the episode · Fast Money: FAA Ground Stop, Anthropic IPO and AI Market Rotation 11/13/26
  4. Guy AdamiPositiveNov 12, 2026· CNBC's "Fast Money"

    Guy Adami holds a long position in Johnson & Johnson.

    “I'm long.”

    Listen at 28:46

    Open the episode · Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven Surge
  5. Guy AdamiPositiveNov 12, 2026· CNBC's "Fast Money"

    Johnson & Johnson stock will rise.

    “J&J is going higher.”

    Listen at 42:14

    Open the episode · Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven Surge
  6. Jim CramerPositiveNov 3, 2026· Mad Money w/ Jim Cramer

    Investors should own Johnson & Johnson stock.

    “Own the stock.”

    Listen at 36:52

    Open the episode · Mad Money w/ Jim Cramer 11/2/26
  7. Jared HolzPositiveOct 14, 2026· Closing Bell

    Johnson & Johnson’s pharmaceutical business is among the best positioned.

    “J&J, even though the stock was down a lot yesterday because of issues they're having in medical devices, that pharma business within J&J looks to be one of the best.”

    Listen at 26:59

    Open the episode · AI Trade Faces a Reality Check 10/14/26
  8. Jim CramerPositiveOct 13, 2026· Mad Money w/ Jim Cramer

    Johnson & Johnson’s post-earnings decline was unjustified.

    “I don't believe J&J deserved to get hit like this.”

    Listen at 19:54

    Open the episode · Mad Money w/ Jim Cramer 10/13/26
  9. Jim CramerPositiveOct 13, 2026· Mad Money w/ Jim Cramer

    Cramer remains bullish on Johnson & Johnson’s investment thesis.

    “My overall thesis for J&J stands.”

    Listen at 24:48

    Open the episode · Mad Money w/ Jim Cramer 10/13/26
  10. Jim CramerPositiveOct 13, 2026· Mad Money w/ Jim Cramer

    Johnson & Johnson has one of the industry’s best drug portfolios.

    “I think this company is one of the best drug portfolios in the industry.”

    Listen at 24:50

    Open the episode · Mad Money w/ Jim Cramer 10/13/26
  11. Jim CramerPositiveOct 13, 2026· Mad Money w/ Jim Cramer

    Johnson & Johnson is an attractive buying opportunity.

    “The bottom line, I think this is a good chance to get into one of the best-performing pharma names out there”

    Listen at 25:50

    Open the episode · Mad Money w/ Jim Cramer 10/13/26
  12. Jim CramerPositiveOct 13, 2026· Mad Money w/ Jim Cramer

    Investors should consider buying Johnson & Johnson after its decline.

    “it might be a good time to do some buying.”

    Listen at 26:04

    Open the episode · Mad Money w/ Jim Cramer 10/13/26
  13. Tim SeymourPositiveOct 13, 2026· CNBC's "Fast Money"

    Johnson & Johnson’s decline is a buying opportunity.

    “So I think this is an opportunity.”

    Listen at 26:40

    Open the episode · Drama in DRAM Memory ETF… And Trading Apple & Others At Record Highs… 10/13/26
  14. Karen FinermanPositiveOct 13, 2026· CNBC's "Fast Money"

    Johnson & Johnson has moved beyond its patent cliff.

    “J&J actually came out on the other side of the patent cliff.”

    Listen at 27:02

    Open the episode · Drama in DRAM Memory ETF… And Trading Apple & Others At Record Highs… 10/13/26
  15. Jim CramerPositiveOct 13, 2026· Mad Money w/ Jim Cramer

    Investors should use Johnson & Johnson’s pullback to buy.

    “I think this pullback in J&J is actually a great chance to get in on one of the best-performing pharma stocks on the market right now.”

    Listen at 27:11

    Open the episode · Mad Money w/ Jim Cramer 10/13/26
  16. Jim CramerPositiveOct 9, 2026· Mad Money w/ Jim Cramer

    Johnson & Johnson ranks among America’s top twenty companies

    “I am willing to say that J&J is a top 20 company in this country.”

    Listen at 4:06

    Open the episode · Mad Money w/ Jim Cramer 10/9/26
  17. Jim CramerPositiveOct 9, 2026· Mad Money w/ Jim Cramer

    Investors should buy Johnson & Johnson after sharp declines

    “J&J needs to be bought when the stock gets crushed.”

    Listen at 4:47

    Open the episode · Mad Money w/ Jim Cramer 10/9/26
  18. Jim CramerPositiveOct 1, 2026· Mad Money w/ Jim Cramer

    Cramer recommends buying Johnson & Johnson.

    “I buy that one.”

    Listen at 6:50

    Open the episode · Mad Money w/ Jim Cramer 10/1/26
  19. Johnson & Johnson ranks ahead of Eli Lilly and Pfizer

    “So I'm going to say J&J, Lilly, and then Pfizer.”

    Listen at 27:22

    Open the episode · Mad Money w/ Jim Cramer 9/3/26
  20. Dan CurtisPositiveJul 28, 2026· Stock Movers

    Johnson & Johnson agreed to commit $5.5 billion toward resolving talc litigation.

    “Johnson Johnson says it has agreed to a $5.5 billion commitment to resolve litigation related to claims that its talc products caused ovarian cancer.”

    Listen at 2:33

    Open the episode · Johnson & Johnson Settlement; Barclays Reports; Applied Digital Rallies
  21. Dan CurtisPositiveJul 28, 2026· Stock Movers

    If signed, the Johnson & Johnson agreement will help close the long-running litigation issue.

    “But but if it's signed, it will help close an issue that's been ongoing for at least 15 years.”

    Listen at 2:50

    Open the episode · Johnson & Johnson Settlement; Barclays Reports; Applied Digital Rallies
  22. Jim CramerPositiveJul 22, 2026· Mad Money w/ Jim Cramer

    Johnson & Johnson’s technology business will matter in future years.

    “Look out, J&J has tech, although it won't matter for a few years.”

    Listen at 3:59

    Open the episode · Mad Money w/ Jim Cramer 7/22/26
  23. Jim CramerPositiveJul 16, 2026· Mad Money w/ Jim Cramer

    Investors should buy Johnson & Johnson after its decline.

    “I would take it.”

    Listen at 6:24

    Open the episode · Mad Money w/ Jim Cramer 7/16/26
  24. Jim CramerPositiveJul 16, 2026· Mad Money w/ Jim Cramer

    Long-term investors should favor Johnson & Johnson or Wells Fargo over margin-driven technology trades.

    “It's much better to take advantage of a mismarked J&J or Wells Fargo for the long term”

    Listen at 8:53

    Open the episode · Mad Money w/ Jim Cramer 7/16/26
  25. Dan CurtisNegativeJul 15, 2026· Stock Movers

    Johnson & Johnson shares fell despite earnings beats and modestly raised 2026 guidance.

    “Johnson and Johnson shares trading under ticker JNJ are down almost 2% in the premarket after the pharma company beat second quarter top and bottom line estimates and the company modestly raised its 2026 sales and profit guidance.”

    Listen at 1:00

    Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO Price
  26. Dan CurtisPositiveJul 15, 2026· Stock Movers

    Johnson & Johnson’s earnings beat was driven by drug growth in several therapeutic areas.

    “The company's beat was driven by growth for its of cancer, inflammatory diseases and treatment resistant depression drugs.”

    Listen at 1:35

    Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO Price
  27. Dan CurtisPositiveJul 15, 2026· Stock Movers

    Johnson & Johnson’s results suggest drug makers are thriving despite regulatory and pricing pressures.

    “This company is suggesting drug makers are thriving despite some recent turmoil at the FDA and some deals with the White House to lower net prices on some medicines.”

    Listen at 1:55

    Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO Price
  28. Jim CramerNegativeJul 15, 2026· Mad Money w/ Jim Cramer

    Cramer expects Johnson & Johnson stock to perform poorly.

    “that's how I think the stock should perform.”

    Listen at 6:00

    Open the episode · Mad Money w/ Jim Cramer 7/15/26
  29. Jim CramerPositiveJul 6, 2026· Mad Money w/ Jim Cramer

    Johnson & Johnson will report favorable news about blockbuster drugs, especially oncology products.

    “I think the company will have lots of good news about its myriad blockbuster drugs, especially its oncological franchise.”

    Listen at 3:43

    Open the episode · Mad Money w/ Jim Cramer 7/6/26
  30. Jim CramerPositiveJul 6, 2026· Mad Money w/ Jim Cramer

    Johnson & Johnson will report cardiovascular market-share gains.

    “I expect some good news about share gains in cardio.”

    Listen at 3:48

    Open the episode · Mad Money w/ Jim Cramer 7/6/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.